옵션 체인은 다양한 행사가격과 만기일에 대한 Foxconn Tech Co의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 Foxconn Tech Co에 대한 시장 심리를 평가합니다..

Foxconn Tech Co (OTC:FXCOF) 주식, 옵션 체인

Foxconn Technology Co Ltd along with its subsidiaries is engaged in manufacturing, processing, and sales of case, heat dissipation modules, and consumer electronics products. The firm's operating segments include Trading services of electronic products and Manufacturing and sales of mechanical components. It generates a majority of its revenue from the Electronic product trading segment. Geographically, the company operates in China, Japan, Taiwan, USA, and others. It generates a majority of its revenue from Japan followed by China.

Deepseek,Ai,App,Seen,On,The,Smartphone,And,Finger,Is

Equities

Large Cap

AAPL

AMZN

BIDU

FXCOF

GOOG

IBTA

INTC

IRBT

NVDA

QCOM

SOUN

SSNLF

소비자 기술 뉴스 (3월 17일~21일): 구글의 위즈 인수 계획, 미국에서 딥시크 금지 조치, 엔비디아의 GTC 2025 행사 등

소비자 기술 뉴스 (3월 17일~21일): 구글의 위즈 인수 계획, 엔비디아의 GTC 2025 행사 등

microsoft shutter

News

Tech

Media

MSFT

마이크로소프트(NASDAQ:MSFT)는 마운트 플레전트(Mount Pleasant)에서 야심차게 추진 중인 데이터센터 프로젝트의 일부 공사를 일시적으로 중단하기로 결정했다. 

마이크로소프트, 33억 달러 규모 데이터센터 건설 일시 중단

FOXCONN TECH CO LTD ORD by Foxconn Technology Co., Ltd.

Foxconn Technology Co Ltd

WIIM

ALZN

Alzamend Neuro shares are trading higher after the company dosed the first patient in its Phase II clinical trial of AL001.

Estrella Immunopharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESLA#NASDAQ">ESLA</a>) ("Estrella" or the "Company"), a clinical stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS&#xAE; T-cell therapies to treat cancer and autoimmune diseases, today announced that the first patient has been dosed in the second cohort of its dose escalation study of Phase I/II STARLIGHT-1 trial for EB103, a CD19-redirected ARTEMIS&#xAE; T-cell therapy to treat patients with Advanced B-Cell Non-Hodgkin's Lymphomas (NHL).
The second cohort will evaluate EB103 at a higher dose level following a review of safety data from the first dose cohort. As previously announced, no dose-limiting toxicities (DLTs) or treatment-related serious adverse events (SAEs) were observed in the first cohort. The initiation of dosing in the second cohort reflects steady progress in Estrella's mission to complete Phase I of STARLIGHT-1.

ESLA

Estrella Immunopharma Announces First Patient Dosed In Second Cohort Of Dose Escalation Study Of Phase I/II STARLIGHT-1 Trial For EB103 To Treat Patients With Advanced B-Cell NHL

Partnership to develop rugged edge AI/ML compute solutions to improve cognitive dominance for U.S. Special Operations Forces
Agreement aligns with OSS' strategy to expand offerings and establish embedded relationships across the U.S. Department of Defense
One Stop Systems, Inc. ("OSS" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OSS#NASDAQ">OSS</a>), a leader in rugged Enterprise Class compute for artificial intelligence (AI), machine learning (ML) and sensor processing at the Edge, today announced that the Company has entered into a Cooperative Research and Development Agreement (CRADA) with U.S. Special Operations Command (USSOCOM) to create advanced, durable High Performance edge Computer (HPeC) solutions that can process vast amounts of data quickly and efficiently in the field.
Under the CRADA, OSS will demonstrate its current, cutting-edge AI and ML computing solutions designed specifically for rugged, edge environments to&nbsp;advance&nbsp;USSOCOM maritime platform performance and capabilities. The partnership leverages OSS' expertise in designing Enterprise Class compute systems that operate in extreme conditions such as harsh climates or remote locations. Solutions under development will support a strategic initiative of USSOCOM, which seeks to enhance the situational awareness, decision-making, and operational capabilities of special operations forces (SOF) in maritime operations. By leveraging AI and ML at the edge, USSOCOM aims to improve cognitive dominance—enabling warfighters to process information faster than their adversaries, to make more informed decisions, and to ultimately achieve mission objectives with greater precision.
"Our collaboration with USSOCOM will provide warfighters with more sophisticated and intelligent tools to improve their performance in increasingly complex and dynamic combat scenarios, thus reinforcing their competitive advantage on the battlefield," commented Robert Kalebaugh, OSS VP of Sales. "SOF's role within the U.S. Department of Defense continues to evolve across echelons, from man-worn to command center operations, and OSS is uniquely qualified to support the needs of U.S. Special Operation Forces."
"Today's announcement also reflects our multi-year strategy focused on expanding our offerings and establishing relationships across all branches of the U.S. Armed Forces. The USSOCOM CRADA represents an important pillar as we continue to forge a relationship with one of the most innovative commands within the Department of Defense. We believe the Armed Forces will accelerate the adaptation of these types of Enterprise Class architecture which OSS provides for AI/ML, sensor fusion and autonomy applications across maritime, land, air, and space domains," concluded Mr. Kalebaugh.

Contracts

One Stop Systems Enters Into Research And Development Agreement With U.S. Special Operations Command To Create Advanced, Durable High Performance Edge Computer Solutions That Can Process Vast Amounts Of Data Quickly And Efficiently In The Field

Stock Split

APDN

Applied DNA To Effect A 1-For-15 Reverse Stock Split On June 2, 2025

Biotech

General

Alzamend Neuro Doses First Patient In Phase II Clinical Trial of AL001

Easily one of the most dominant enterprises in recent memory is Palantir Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>). A big data analytics specialist, Palantir has been a massive beneficiary of the boom in artificial intelligence. Since the start of this year, PLTR stock has gained nearly 64% of equity value, easily leapfrogging the Nasdaq Composite index, which is down 1% during the same period. Still, valuation concerns impose a dark cloud over PLTR's prospects.
On the business front, it's difficult to argue against Palantir's dominance, especially in the realm of the defense industry. Recently, PLTR stock popped higher thanks to the Department of Defense awarding the underlying company a<a href="https://www.benzinga.com/25/05/45572000/palantir-stock-is-trading-higher-thursday-whats-going-on"> $795 million modification</a> to a contract for its Maven Smart System software licenses.
Initially, the deal was announced last year as a $480 million fixed, firm-price contract. However, with the modification, the terms of the agreement bring the total contract value up to nearly $1.28 billion. Fundamentally, the upgrade demonstrates the core influence that Palantir has achieved in its primary market.
In addition, Palantir is making significant inroads into the commercial sector. Notably, the company's Artificial Intelligence Platform (AIP) is gaining traction, allowing it to partner with major corporations. Indeed, Wedbush analyst Dan Ives believes that PLTR stock will command a<a href="https://www.benzinga.com/25/05/45232694/palantir-stock-shows-momentum-with-q1-results-ai-opportunity-analyst-says-generation-tech-name-worth-1-trillion-in-future"> trillion-dollar market capitalization</a> over the next three years.
Still, not everyone is convinced about Palantir's stratospheric run. One of the most notable criticisms centers on<a href="https://www.macrotrends.net/stocks/charts/PLTR/palantir-technologies/pe-ratio"> valuation</a>. As of this moment, PLTR stock trades at over 538-times trailing-12-month earnings. About a year ago, this metric was around 149 times – which was still a lofty figure. The anxiety, then, is that early investors will head for the exits.
This isn't just an empty sentiment. This year, the predominant transaction type among<a href="https://www.benzinga.com/quote/PLTR/insider-trades"> insider activity</a> for PLTR stock was sell orders, either for the equity or its options. To be fair, insiders sell stock for a variety of reasons, many of them mundane. Nevertheless, it's not the most encouraging sign when insiders – the folks that know the business the best – head for the exits.
The Direxion ETFs: While the trajectory of PLTR stock this year has been largely one-sided, there's more than enough room for skepticism – and that suits financial services provider Direxion perfectly. Thanks to its PLTR-focused bull and bear exchange-traded funds, traders can easily speculate on the tech specialist's fortunes (or misfortunes).
For the optimists, they may consider the Direxion Daily PLTR Bull 2X Shares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTU#NASDAQ">PLTU</a>), which seeks the daily investment results, before fees and expenses, of 200% of the performance of PLTR stock. Conversely, the pessimists may be intrigued by the Direxion Daily PLTR Bear 1X Shares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTD#NASDAQ">PLTD</a>), which tracks 100% of the inverse performance of the namesake equity.
Primarily, the main functionality of these specialized ETFs is to offer convenient mechanisms for speculation. Typically, those interested in utilizing leverage or engaging in short positions must trade options. While derivative financial instruments offer incredible flexibility, they're also complex vehicles with unique risk-reward profiles. With Direxion ETFs, the units can be bought and sold much like any other public security, thus easing the learning curve.
Still, there are serious risks to consider. First, both leveraged and inverse ETFs tend to be more volatile than standard bread-and-butter funds. Second, PLTU and PLTD were designed for exposure lasting no longer than one day. Holding onto these funds for longer than the recommended period may lead to value decay due to the daily compounding effect.
The PLTU ETF: Since the start of this year, the Direxion Daily PLTR Bull 2X Shares nearly doubled in value thanks to the robust performance of PLTR stock.
<ul class="wp-block-list">
<li>Currently, technical momentum in the PLTU ETF is robust, with the bull fund above both its 50-day moving average (DMA) and its 20-day exponential moving average (EMA).</li>
<li>One concern to note is that May's rising price action has been met with declining volume. Ideally, rising volume should confirm rising price, thus warranting caution.</li>
</ul>
<figure class="wp-block-image"><img loading="lazy" decoding="async" width="1037" height="618" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/29075921/image-382.png" alt="" class="wp-image-931425" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/29075921/image-382.png 1037w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/29075921/image-382-300x184.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/29075921/image-382-1024x628.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/29075921/image-382-768x471.png 768w" sizes="(max-width: 1037px) 100vw, 1037px" /></figure>
The PLTD ETF: Predictably, the year-to-date performance of the Direxion Daily PLTR Bear 1X Shares has been poor, with the bear fund losing more than 54%.
<ul class="wp-block-list">
<li>In a picture of contrasts, the PLTD ETF is conspicuously below both its 50 DMA and its 20 EMA, reflecting deep pessimism.</li>
<li>At the same time, the inverse fund is attempting to develop a baseline at the $10.50 level. If so, a quick reversal toward the $11 mark isn't out of the question.</li>
</ul>
<figure class="wp-block-image"><img loading="lazy" decoding="async" width="1036" height="635" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/29075921/image-382.png" alt="" class="wp-image-931426" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/29075921/image-382.png 1036w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/29075921/image-382-300x184.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/29075921/image-382-1024x628.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/29075921/image-382-768x471.png 768w" sizes="(max-width: 1036px) 100vw, 1036px" /></figure>
Featured image by <a href="https://pixabay.com/users/thedigitalartist-202249/?utm_source=link-attribution&amp;utm_medium=referral&amp;utm_campaign=image&amp;utm_content=7186533">Pete Linforth</a> from <a href="https://pixabay.com/illustrations/big-data-data-information-binary-7186533/">Pixabay</a>.

Long Ideas

Short Ideas

Technicals

Trading Ideas

ETFs

PLTD

PLTR

PLTU

Productivity Clashes With Premium Valuations For Direxion's PLTR-Focused Bull And Bear Funds

<ul>
<li>CC-42344 was shown to be highly active against the highly pathogenic 2024 Texas H5N1 avian influenza strain</li>
<li>The Company's virology study further confirmed the previous structural and in vitro data that revealed the binding of CC-42344 to PB2 protein of the 2024 H5N1 avian influenza virus</li>
</ul>
BOTHELL, Wash., May 29, 2025 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=a2lvSGEYfO0wnqCxWhGN5Th2eyiuG47RucIAbJQEGzvjuCfbXbv1Ec0_EkxdTb7h66djGR5DLGdfjb8IPoG_D23fZs9axyH_vboP8qCGanQ=">Cocrystal Pharma, Inc</a>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COCP#NASDAQ">COCP</a>) announces that a recent virology study showed its novel, broad-spectrum influenza PB2 inhibitor CC-42344 exhibits strong antiviral activity against the highly pathogenic H5N1 avian influenza A strain (A/Texas/37/2024).
On March 25, 2024, the highly pathogenic avian H5N1 influenza virus was confirmed in a dairy cow in Texas and has continued to spread widely in U.S. dairy cattle, causing a few human cases. There is concern that the H5N1 virus could adapt for human-to-human transmission and potentially result in an influenza pandemic. CC-42344 is a new investigational drug candidate for the treatment of pandemic and seasonal influenza infections. This inhibitor binds to a highly conserved active site of the PB2 protein and inhibits the viral replication process. The Company previously announced the structural and in vitro data of CC-42344 with the purified H5N1 PB2 protein.
The virology study utilized the highly pathogenic H5N1 avian strain (influenza A/Texas/37/2024) and was conducted to test antiviral activity of CC-42344 using Tamiflu&#xAE; as a reference inhibitor. The data showed that CC-42344 was highly potent against the H5N1 avian influenza virus (EC50, 0.003 µM), approximately 1,000-fold more potent, compared to a refence compound Tamiflu (EC50, 2.69 µM). CC-42344 is currently in development as an oral treatment for pandemic avian and seasonal influenza A infections with initial data showing a favorable safety and tolerability profile.

COCP

Cocrystal Pharma's Recent Virology Study Shows Broad-Spectrum Influenza PB2 Inhibitor CC-42344 Exhibits Strong Antiviral Activity Against Highly Pathogenic H5N1 Avian Influenza A Strain

PODC

PodcastOne Acquires New Podcasts, Marking 11 Additions In 2025

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.RevBiosciences.com&amp;esheet=54261915&amp;newsitemid=20250529009291&amp;lan=en-US&amp;anchor=Revelation+Biosciences%2C+Inc.&amp;index=1&amp;md5=9e09ccbaa4de8f68db344a0670de27f0">Revelation Biosciences, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REVB#NASDAQ">REVB</a>) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, today announced the pricing of a public offering of 3,640,000 shares of its common stock (or common stock equivalents), together with warrants to purchase up to 14,560,000 shares of its common stock at an offering price to the public of $1.10 per share and associated warrant. The warrants will have an exercise price of $1.10 per share, are exercisable beginning on the effective date of stockholder approval of the issuance of the shares upon exercise of the warrants, and will expire five years following the initial exercise date. The closing of the offering is expected to occur on or about May 29, 2025, subject to the satisfaction of customary closing conditions.
Roth Capital Partners is acting as sole placement agent for the offering.
The gross proceeds to the Company from the offering are expected to be approximately $4 million, before deducting the placement agent's fees and other offering expenses payable by Revelation. The Company intends to use the net proceeds from this offering to further the development of our product candidates, including (i) the completion of our ongoing Phase 1b clinical study, (ii) the manufacture of clinical drug supply, (iii) additional preclinical work for multiple indications, (iv) continue to develop other products and therapies, and (v) fund working capital and general corporate purposes using any remaining amounts.
&nbsp;

Offerings

REVB

Revelation Biosciences Announces Pricing Of $4M Public Offering Of Up To 14.56M Shares AT An Offering Price Of $1.10/Shr

NextDecade Corporation (NextDecade or the Company) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEXT#NASDAQ">NEXT</a>) announced today that it has executed a 20-year liquefied natural gas (LNG) sale and purchase agreement (SPA) with JERA for offtake from Train 5 at the Rio Grande LNG Facility.
Under the terms of the SPA, JERA will purchase 2.0 million tonnes per annum (MTPA) of LNG for 20 years on a free on board basis at a price indexed to Henry Hub, subject to a positive Final Investment Decision (FID) on Train 5.
Achieving a positive FID on Train 5 will be subject to, among other things, entering into appropriate commercial arrangements, entering into an engineering, procurement, and construction agreement, and obtaining adequate financing to construct Train 5 and related infrastructure.

NextDecade Executes 20-Year Liquefied Natural Gas Sale And Purchase Agreement With JERA For Offtake From Train 5 At Rio Grande LNG Facility

In the preceding three months, 12 analysts have released ratings for Macy's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/M#NYSE">M</a>), presenting a wide array of perspectives from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">10</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Macy's, presenting an average target of $13.33, a high estimate of $17.00, and a low estimate of $8.00. Experiencing a 12.19% decline, the current average is now lower than the previous average price target of $15.18. 
<img src="https://www.benzinga.com/files/images/story/2025/1748520077_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Macy's. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$14.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Alex Straton</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$12.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Paul Kearney</td>
<td>Barclays</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$12.00</td>
<td>-</td>
</tr>
<tr>
<td>Brooke Roach</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$12.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Paul Lejuez</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$11.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Matthew Boss</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$13.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Market Perform</td>
<td>$15.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Paul Lejuez</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$14.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Brooke Roach</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$17.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Jay Sole</td>
<td>UBS</td>
<td>Lowers</td>
<td>Sell</td>
<td>$8.00</td>
<td>$9.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$15.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Market Perform</td>
<td>$17.00</td>
<td>$17.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Macy's. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Macy's compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Macy's's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Macy's's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/M/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Macy's analyst ratings.</a>
<h2>Unveiling the Story Behind Macy's</h2>
Founded in 1858 and based in New York City, Macy's operates about 450 stores under the Macy's nameplate, nearly 60 stores under the Bloomingdale's (full-price and outlet) and Bloomie's nameplates, and more than 170 freestanding Bluemercury specialty beauty stores. Macy's also operates e-commerce sites and licenses Bloomingdale's stores in the United Arab Emirates and Kuwait. Women's apparel, accessories, shoes, cosmetics, and fragrances constitute about 62% of Macy's sales.
<h3>Macy's's Financial Performance</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Challenges: Macy's's revenue growth over 3M faced difficulties. As of 31 January, 2025, the company experienced a decline of approximately -4.39%. This indicates a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Consumer Discretionary sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 4.27%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 7.86%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Macy's's ROA excels beyond industry benchmarks, reaching 2.03%. This signifies efficient management of assets and strong financial health.
Debt Management: Macy's's debt-to-equity ratio is notably higher than the industry average. With a ratio of 1.25, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>How Are Analyst Ratings Determined?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Breaking Down Macy's: 12 Analysts Share Their Views

In the latest quarter, 9 analysts provided ratings for Intellia Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTLA#NASDAQ">NTLA</a>), showcasing a mix of bullish and bearish perspectives.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Intellia Therapeutics, presenting an average target of $32.67, a high estimate of $68.00, and a low estimate of $10.00. Highlighting a 23.0% decrease, the current average has fallen from the previous average price target of $42.43. 
<img src="https://www.benzinga.com/files/images/story/2025/1748520054_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The standing of Intellia Therapeutics among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mitchell Kapoor</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$30.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Mitchell Kapoor</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$30.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>David Nierengarten</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$10.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Debjit Chattopadhyay</td>
<td>Guggenheim</td>
<td>Lowers</td>
<td>Buy</td>
<td>$45.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>David Lebowitz</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$10.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Geulah Livshits</td>
<td>Chardan Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$68.00</td>
<td>$68.00</td>
</tr>
<tr>
<td>Andy Chen</td>
<td>Wolfe Research</td>
<td>Announces</td>
<td>Outperform</td>
<td>$21.00</td>
<td>-</td>
</tr>
<tr>
<td>Mitchell Kapoor</td>
<td>HC Wainwright &amp; Co.</td>
<td>Announces</td>
<td>Buy</td>
<td>$30.00</td>
<td>-</td>
</tr>
<tr>
<td>Joon Lee</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$50.00</td>
<td>$90.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Intellia Therapeutics. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Intellia Therapeutics compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Intellia Therapeutics's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/NTLA/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Intellia Therapeutics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Delving into Intellia Therapeutics's Background</h2>
Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
<h3>Unraveling the Financial Story of Intellia Therapeutics</h3>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Decline in Revenue: Over the 3M period, Intellia Therapeutics faced challenges, resulting in a decline of approximately -42.54% in revenue growth as of 31 March, 2025. This signifies a reduction in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -687.61%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of -13.84%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Intellia Therapeutics's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -10.5%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.15.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

NTLA

Demystifying Intellia Therapeutics: Insights From 9 Analyst Reviews

Ratings for C3.ai (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AI#NYSE">AI</a>) were provided by 3 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated C3.ai and provided 12-month price targets. The average target is $18.33, accompanied by a high estimate of $20.00 and a low estimate of $17.00. This current average has decreased by 27.64% from the previous average price target of $25.33. 
<img src="https://www.benzinga.com/files/images/story/2025/1748520041_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive C3.ai. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eric Heath</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$17.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Sanjit Singh</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$20.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Gil Luria</td>
<td>DA Davidson</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$18.00</td>
<td>$25.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to C3.ai. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of C3.ai compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of C3.ai's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of C3.ai's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/AI/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on C3.ai analyst ratings.</a>
<h2>Unveiling the Story Behind C3.ai</h2>
C3.ai Inc is an enterprise artificial intelligence company. The company provides software-as-a-service applications that enable customers to rapidly develop, deploy, and operate large-scale Enterprise AI applications across any infrastructure. It provides solutions under three divisions namely, The C3 AI Platform, which is an end-to-end application development and runtime environment for designing, developing, and deploying AI applications: C3 AI Applications, which is a portfolio of pre-built, extensible, industry-specific, and application-specific Enterprise AI applications: and C3 Generative AI, which combines the utility of large language models. Geographically the company derives revenue from North America, Europe, the Middle East and Africa, Asia Pacific, and the Rest of the World.
<h3>Key Indicators: C3.ai's Financial Health</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: C3.ai's revenue growth over a period of 3M has been noteworthy. As of 31 January, 2025, the company achieved a revenue growth rate of approximately 26.0%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Information Technology sector.
Net Margin: C3.ai's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -81.19%, the company may face hurdles in effective cost management.
Return on Equity (ROE): C3.ai's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -9.33%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): C3.ai's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -7.63%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: C3.ai's debt-to-equity ratio is below the industry average at 0.01, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: Simplified</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Forecasting The Future: 3 Analyst Projections For C3.ai

Veeva Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) underwent analysis by 10 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $255.2, a high estimate of $300.00, and a low estimate of $201.00. This upward trend is apparent, with the current average reflecting a 1.43% increase from the previous average price target of $251.60.
<img src="https://www.benzinga.com/files/images/story/2025/1748520028_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Veeva Systems. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ryan MacDonald</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$300.00</td>
<td>$270.00</td>
</tr>
<tr>
<td>Brent Bracelin</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$255.00</td>
<td>$290.00</td>
</tr>
<tr>
<td>Sangita Jain</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$250.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>Anne Samuel</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$249.00</td>
<td>$218.00</td>
</tr>
<tr>
<td>Allan Verkhovski</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$245.00</td>
<td>$240.00</td>
</tr>
<tr>
<td>Craig Hettenbach</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Underweight</td>
<td>$201.00</td>
<td>$195.00</td>
</tr>
<tr>
<td>Joe Meares</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$217.00</td>
<td>$210.00</td>
</tr>
<tr>
<td>Jeff Garro</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$280.00</td>
<td>$280.00</td>
</tr>
<tr>
<td>Joe Vruwink</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$285.00</td>
<td>$283.00</td>
</tr>
<tr>
<td>Ryan MacDonald</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$270.00</td>
<td>$270.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Veeva Systems. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Veeva Systems compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Veeva Systems's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Veeva Systems's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/VEEV/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Veeva Systems analyst ratings.</a>
<h2>Discovering Veeva Systems: A Closer Look</h2>
Veeva is the global leading supplier of cloud-based software solutions for the life sciences industry. The company's best-of-breed offerings address operating and regulatory requirements for customers ranging from small, emerging biotechnology companies to departments of global pharmaceutical manufacturers. The company leverages its domain expertise to improve the efficiency and compliance of the underserved life sciences industry, displacing large, highly customized and dated enterprise resource planning systems that have limited flexibility. Its two main products are Veeva CRM, a customer relationship management platform for companies with a salesforce, and Veeva Vault, a content management platform that tackles various functions within any life sciences company.
<h3>A Deep Dive into Veeva Systems's Financials</h3>
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Revenue Growth: Veeva Systems's revenue growth over a period of 3M has been noteworthy. As of 31 January, 2025, the company achieved a revenue growth rate of approximately 14.31%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 27.14%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Veeva Systems's ROE stands out, surpassing industry averages. With an impressive ROE of 3.45%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Veeva Systems's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 2.84%, the company showcases efficient use of assets and strong financial health.
Debt Management: Veeva Systems's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.01.
<h2>Analyst Ratings: Simplified</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

VEEV

10 Analysts Assess Veeva Systems: What You Need To Know

Veeva Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) raises FY2026 Adj EPS guidance from $7.32 to $7.63 vs $7.30 analyst estimate. Raises FY2026 sales outlook from $3.04 billion-$3.06 billion to $3.09 billion-$3.10 billion vs $3.06 billion estimate.

Guidance

Reported Earlier, Veeva Systems Raises FY2026 Adj EPS Guidance from $7.32 to $7.63 vs $7.30 Est; Raises FY2026 Sales Guidance from $3.04B-$3.06B to $3.09B-$3.10B vs $3.06B Est

RBC Capital analyst Rishi Jaluria downgrades Salesforce (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRM#NYSE">CRM</a>) from Outperform to Sector Perform and lowers the price target from $420 to $275.

Downgrades

Price Target

RBC Capital Downgrades Salesforce to Sector Perform, Lowers Price Target to $275

Management

Koppers Holdings Appoints James A. Sullivan President; Effective June 1, 2025

ALMS

Alumis Completes Patient Enrollment In Pivotal Phase 3 ONWARD Clinical Program Of ESK-001 For Treatment Of Moderate-To-Severe Plaque Psoriasis

President Donald Trump has been dealt a significant blow to his trade policies, with a federal court ruling against his authority to impose global tariffs. However, the president is likely to find a workaround to this setback.
What Happened: Goldman Sachs economists believe that the court&#8217;s decision will only be a temporary obstacle, as the Trump administration has other legal ways of imposing tariffs. These include Section 122 of the Trade Act of 1974, Section 301 investigations and Section 338 of the Trade Act of 1930, <a href="https://www.cnbc.com/2025/05/29/trump-expected-to-find-a-workaround-after-trade-court-blocks-tariffs.html">reported</a> CNBC.
Section 122 allows the administration to swiftly impose tariffs—up to 15%—without a formal investigation, offering a quick workaround to court obstacles. However, Goldman analysts note the measure would expire after 150 days unless Congress intervenes.
Meanwhile, Section 232 tariffs on steel, aluminum, and autos may be expanded to other sectors, while Section 338 permits the president to impose up to 50% tariffs on imports from countries that discriminate against the U.S.
The White House could shift its focus from targeting specific countries to targeting industries instead — an approach that rests on more solid legal footing, as per Goldman Sachs.
Steven Blitz, TS Lombard&#8216;s chief U.S. economist, opined, "The first thing he will probably do is an emergency appeal to the Supreme Court … wanting to get a ruling from them that basically says you can keep these tariffs in place while the appeals process runs through."
Speaking about the Trump Administration&#8217;s appeal within minutes, Deutsche Bank's Jim Reid said a note, "We should say at the outset that this is hardly the end of this story,&#8221; reported Fortune. 
SEE ALSO: <a href="https://benzinga.com/25/05/45664572/us-stocks-likely-to-open-higher-after-federal-court-invalidates-trumps-tariffs-without-tariff-revenues-there-is-a-big-beautiful-hole-in-the-big-beautiful-budget-bill-says-expert" target="_blank" rel="noreferrer noopener">US Stocks Likely To Open Higher After Federal Court Blocks Trump&#8217;s Tariffs: &#8216;Without Tariff Revenues, There Is A Big Beautiful Hole In The Big Beautiful Budget Bill,&#8217; Says Expert</a>
Why It Matters: The court&#8217;s ruling could have a significant impact on the administration&#8217;s trade strategies. The decision, delivered by the U.S. Court of International Trade, could potentially <a href="https://www.benzinga.com/news/25/05/45660322/trump-tariffs-struck-down-by-federal-court-major-blow-to-white-houses-trade-strategy-report">halt </a>the administration&#8217;s trade war efforts.
Legal experts and economists have supported the court&#8217;s decision stating that the President was wrong to claim a virtually unlimited power to impose tariffs. However, some economists in the past stated that Trump tariffs are &#8216;addictive&#8217; and could remain in place even if the Democrats come <a href="https://www.benzinga.com/news/25/05/45556999/addictive-trump-tariffs-are-here-to-stay-even-if-democrats-come-back-to-power-says-wharton-professor">back to power</a> as they may not want to discontinue the lucrative revenue stream. 
Meanwhile, China has already responded to the court&#8217;s decision, calling on the United States to <a href="https://www.benzinga.com/markets/25/05/45664337/china-tells-us-to-entirely-revoke-wrongful-unilateral-tariffs-after-court-blocks-trumps-liberation-day-levies">entirely withdraw</a> the unilateral tariff measures that the court blocked.
Despite the setback, Trump is expected to find a way around the court&#8217;s ruling, potentially using other legal means to impose tariffs. The market reaction to the ruling has been mixed, with equity&nbsp;markets around the world broadly&nbsp;rising, while the reaction in Europe has been more muted.
During Thursday&#8217;s pre-market, The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and  Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) rose 1.06% and 1.55%, respectively.
<ul class="wp-block-list">
<li>READ MORE: <a href="https://benzinga.com/25/05/45661076/peter-schiff-challenges-jd-vances-bitcoins-safe-haven-assertion-urges-him-to-implement-policies-that-reduce-the-need-to-hedge" target="_blank" rel="noreferrer noopener">JD Vance Said Bitcoin Created Wealth, Peter Schiff Says It Did No Such Thing: &#8216;What Has Happened Is A Massive Transfer Of …&#8217; &#8211; Benzinga</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Markets

'Hardly The End Of This Story:' Trump Has Several Legal Options To Maintain Tariffs Despite Federal Court Ruling, Experts Say

WGRX

Wellgistics Health Announces Preliminary Inclusion In Russell 2000 And Russell 3000 Indexes, As Part Of 2025 Russell US Indexes Annual Reconstitution

Foxconn Tech Co

Comments

Foxconn Tech Co

Foxconn Tech Co (FXCOF) 옵션

No option chain data available. Please try again later

뉴스

파트너 / 기고자

벤징가 글로벌